deepCDR is Responding to COVID-19
The race is on for biotechnology companies to produce therapeutic, prophylactic and diagnostics methods to SARS-CoV-2 infection. Our team is ready to absorb the high influx of demand for our antibody engineering services. We are partnering with the world’s leading companies to rapidly bring their SARS-CoV-2 antibody leads into preclinical and clinical studies.
Using our proprietary deep learning methods we are helping our customers increase the quality of their Antibody development programs by addressing manufacturing and immunogenic liabilities. For customers working on SARS-CoV-2, we are able to bring optimization projects down to half their original timeline from reception of candidate sequence(s) to optimized lead(s), i.e. within 8 weeks.
Patient Repertoire Analysis and Library Design
Using our proprietary deep sequencing and deep learning methods we are able to quickly provide our customers with patient repertoire analysis based on single or multiple patients. For customers working on SARS-CoV-2 we are able to bring Library build projects down to half their original timespan, i.e. within 4 weeks.
Antibody Design for Diagnostic Purposes
Our design workflow is also well adapted to customers working on the diagnostic end of SARS-CoV-2, in particular those developing Antibodies with improved specificity and affinity for ELISA-based assays.
Please contact us for further licensing and partnering opportunities.